Cargando…

BATF Potentially Mediates Negative Regulation of PD-1/PD-Ls Pathway on T Cell Functions in Mycobacterium tuberculosis Infection

Background: Previously, we have found that blockade of PD-1/PD-Ls pathway could enhance CD4(+) T cells-mediated protective immunity in patients with active tuberculosis (ATB). However, the mechanism of PD-1/PD-Ls pathway involved in negative regulation of anti-TB immunity has been still unclear. Rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Qianqian, Ou, Qinfang, Shen, Lei, Qiu, Chao, Zhang, Bingyan, Zhang, Wenhong, Shao, Lingyun, Gao, Yan, Chen, Zheng W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803382/ https://www.ncbi.nlm.nih.gov/pubmed/31681314 http://dx.doi.org/10.3389/fimmu.2019.02430

Ejemplares similares

PD-1/PD-L pathway inhibits M.tb-specific CD4(+) T-cell functions and phagocytosis of macrophages in active tuberculosis
por: Shen, Lei, et al.
Publicado: (2016)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
por: Pesce, Silvia, et al.
Publicado: (2019)

BATF relieves hepatic steatosis by inhibiting PD1 and promoting energy metabolism
por: Zhang, Zhiwang, et al.
Publicado: (2023)

Differential expression of CD64 in patients with Mycobacterium tuberculosis infection: A potential biomarker for clinical diagnosis and prognosis
por: Liu, Qianqian, et al.
Publicado: (2020)

Downregulation of the PD-1/PD-Ls pathway in peripheral cells correlates with asbestosis severity
por: Qiu, Meihua, et al.
Publicado: (2021)

Characterization of multiple soluble immune checkpoints in individuals with different Mycobacterium tuberculosis infection status and dynamic changes during anti-tuberculosis treatment
por: Chen, Huaxin, et al.
Publicado: (2022)

A combination of the QuantiFERON-TB Gold In-Tube assay and the detection of adenosine deaminase improves the diagnosis of tuberculous pleural effusion
por: Liu, Yuanyuan, et al.
Publicado: (2016)

PD-1 Expression on Mycobacterium tuberculosis-Specific CD4 T Cells Is Associated With Bacterial Load in Human Tuberculosis
por: Day, Cheryl L., et al.
Publicado: (2018)

Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma
por: Ma, Li-Jie, et al.
Publicado: (2018)

Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1
por: Cai, Hao, et al.
Publicado: (2021)

Potential diagnostic value of serum/pleural fluid IL-31 levels for tuberculous pleural effusion
por: Gao, Yan, et al.
Publicado: (2016)

Differential expression and predictive value of monocyte scavenger receptor CD163 in populations with different tuberculosis infection statuses
por: Liu, Qianqian, et al.
Publicado: (2019)

CD36-BATF2\MYB Axis Predicts Anti-PD-1 Immunotherapy Response in Gastric Cancer
por: Jiang, Qiuyu, et al.
Publicado: (2023)

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
por: Khan, Muhammad, et al.
Publicado: (2023)

A PD-L1 Negative Advanced Gastric Cancer Patient With a Long Response to PD-1 Blockade After Failure of Systematic Treatment: A Case Report
por: Zhang, Fangyuan, et al.
Publicado: (2021)

Assessing and screening for T-cell epitopes from Mycobacterium tuberculosis RD2 proteins for the diagnosis of active tuberculosis
por: Chen, Jiazhen, et al.
Publicado: (2018)

Characterization of the Clinical Significance of PD-1/PD-Ls Expression and Methylation in Patients With Low-Grade Glioma
por: Mei, Jie, et al.
Publicado: (2021)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
por: Qin, Weiting, et al.
Publicado: (2019)

Role of regulation of PD-1 and PD-L1 expression in sepsis
por: Zhang, Teng, et al.
Publicado: (2023)

Late prosthetic valve endocarditis with Mycobacterium tuberculosis after the Bentall procedure
por: Liu, Qianqian, et al.
Publicado: (2019)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
por: Wang, Yusha, et al.
Publicado: (2022)

B21 DNA vaccine expressing ag85b, rv2029c, and rv1738 confers a robust therapeutic effect against latent Mycobacterium tuberculosis infection
por: Weng, Shufeng, et al.
Publicado: (2022)

Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis
por: Liu, Kewei, et al.
Publicado: (2022)

Transcriptional Profiling of Human Peripheral Blood Mononuclear Cells Identifies Diagnostic Biomarkers That Distinguish Active and Latent Tuberculosis
por: Wang, Sen, et al.
Publicado: (2019)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

BATF3 Protects Against Metabolic Syndrome and Maintains Intestinal Epithelial Homeostasis
por: Hamade, Hussein, et al.
Publicado: (2022)

Tox induces T cell IL-10 production in a BATF-dependent manner
por: Canaria, D. Alejandro, et al.
Publicado: (2023)

PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis
por: Yu, Yinan, et al.
Publicado: (2023)

Suppression of FOXP3 expression by the AP-1 family transcription factor BATF3 requires partnering with IRF4
por: Arnold, Preston R., et al.
Publicado: (2022)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
por: Jiang, Siqing, et al.
Publicado: (2022)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer
por: Huang, Renhong, et al.
Publicado: (2023)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2018)

Targeting the PD-1/PD-L1 Axis in Human Vitiligo
por: Willemsen, Marcella, et al.
Publicado: (2020)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
por: Zhang, Yuedi, et al.
Publicado: (2022)

The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?
por: Jiang, Aimin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_57kljnd4suu7rqd6534m7apafm